Study of hypoglycemic activity of Subetta and rosiglitazone on the model of streptozotocin-induced diabetes mellitus in rats.
Antidiabetic activity of Subetta was revealed on the model of streptozotocin-induced diabetes mellitus in rats. Intragastric administration of this preparation in a dose of 5 ml/kg for 50 days reduced blood glucose levels, urine levels of glucose and ketone bodies, restored glucose tolerance in the oral glucose test, improved general condition and increased the survival rate of animals. The effectiveness of the drug was not inferior to that of rosiglitazone (8 mg/kg).
Materia Medica Holding, Moscow, Russia. nauka@materiamedica.ru
I A
IA
Kheyfets
A A
AA
Spasov
M P
MP
Voronkova
J L
JL
Dugina
O I
OI
Epstein
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D000906:Antibodies; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; C000608938:subetta; D000077154:Rosiglitazone